[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE76747T1 - Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. - Google Patents

Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Info

Publication number
ATE76747T1
ATE76747T1 AT87107979T AT87107979T ATE76747T1 AT E76747 T1 ATE76747 T1 AT E76747T1 AT 87107979 T AT87107979 T AT 87107979T AT 87107979 T AT87107979 T AT 87107979T AT E76747 T1 ATE76747 T1 AT E76747T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
methyl ester
preparation
compositions containing
therapeutic uses
Prior art date
Application number
AT87107979T
Other languages
English (en)
Inventor
Paolo Chiesi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT20737/86A external-priority patent/IT1190342B/it
Priority claimed from IT19221/87A external-priority patent/IT1203321B/it
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE76747T1 publication Critical patent/ATE76747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87107979T 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. ATE76747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT20737/86A IT1190342B (it) 1986-06-10 1986-06-10 Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche
IT19221/87A IT1203321B (it) 1987-01-30 1987-01-30 Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche
EP87107979A EP0252290B1 (de) 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische Zusammensetzungen, ihre Herstellung und therapeutische Verwendungen

Publications (1)

Publication Number Publication Date
ATE76747T1 true ATE76747T1 (de) 1992-06-15

Family

ID=26327098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87107979T ATE76747T1 (de) 1986-06-10 1987-06-02 Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Country Status (13)

Country Link
US (2) US4826875A (de)
EP (1) EP0252290B1 (de)
JP (1) JP2572768B2 (de)
KR (2) KR880000092A (de)
AT (1) ATE76747T1 (de)
AU (1) AU605154B2 (de)
CA (1) CA1303509C (de)
DE (2) DE252290T1 (de)
ES (1) ES2042520T3 (de)
GR (1) GR880300058T1 (de)
HU (1) HUT43952A (de)
NZ (1) NZ220631A (de)
PT (1) PT85055B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
DE4325435A1 (de) * 1993-07-29 1995-02-02 Basf Ag Neue Wirkstoffkombination
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
CZ297382B6 (cs) * 1995-03-02 2006-11-15 R.P. Scherer Limited Rychle se dispergující orální pevná dávková formafarmaceutického prostredku pro lécení Parkinsonovy nemoci
JPH11506744A (ja) 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JPH11504944A (ja) * 1995-11-06 1999-05-11 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレギリンの舌下およびバッカル投与
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
WO1998027055A1 (en) 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
AU764844B2 (en) 1998-11-10 2003-09-04 Teva Pharmaceutical Industries Ltd. Process for manufacture of L-DOPA ethyl ester
EP1135118A1 (de) 1998-11-10 2001-09-26 Teva Pharmaceutical Industries Ltd. Dispersierbare zusammenstellung die den ethylester des l-dopa enthält
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
AU2001296703A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
KR100894465B1 (ko) * 2003-10-20 2009-04-22 테바 파마슈티컬 인더스트리즈 리미티드 레보도파의 지속적 효과를 위한 조성물 및 제형
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
DK1751087T3 (da) * 2004-06-04 2012-07-16 Xenoport Inc Levodopa-derivater og sammensætninger og anvendelser deraf
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006051154A1 (en) 2004-11-10 2006-05-18 Orion Corporation Treatment of restless legs syndrome
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
ES2391575T3 (es) * 2005-12-05 2012-11-27 Xenoport, Inc. Mesilato de profármaco de Levodopa, sus composiciones y sus usos
BRPI0620659A2 (pt) * 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
BRPI0708071A8 (pt) * 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
EP2125702A1 (de) * 2006-12-21 2009-12-02 Xenoport, Inc. Levodopadimethylsubstituierte diester-prodrugs, zusammensetzungen und verwendungsverfahren
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008213772A1 (en) 2007-02-06 2008-08-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Composition comprising terpene compounds and methods for inhibiting nerve transmission
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
CN101283965B (zh) * 2007-10-26 2010-06-16 南京长澳医药科技有限公司 一种含左旋多巴甲酯的制剂及制备方法
WO2009085306A1 (en) 2007-12-28 2009-07-09 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
JP2011530543A (ja) 2008-08-13 2011-12-22 ニューロクエスト インク 感覚欠損を治療するための組成物および方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
JP2012505885A (ja) * 2008-10-20 2012-03-08 ゼノポート，インコーポレーテッド レボドパエステルプロドラッグを合成する方法
US8286311B2 (en) 2008-10-31 2012-10-16 Jisook Paik Buckle
EP2421367A4 (de) * 2009-04-23 2012-05-23 Univ Cincinnati Verabreichung von allantoin zur behandlung von neurodegenerativen erkrankungen und neurotrauma
KR101641401B1 (ko) 2009-05-19 2016-07-20 뉴로덤 엘티디 Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
KR101196354B1 (ko) 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
WO2012066538A1 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
JP2014508113A (ja) * 2010-12-10 2014-04-03 シンアジャイル コーポレーション 皮下注入可能なレボドパプロドラッグ組成物及び注入方法
CN107693486A (zh) 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
EP2968371A4 (de) 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation der reparaturaktivität zellulärer dna zur interzeption von malignität
EP2967073B9 (de) 2013-03-15 2019-04-10 Bristol-Myers Squibb Company Lxr-modulatoren
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
PL3054929T3 (pl) 2013-10-07 2021-05-31 Impax Laboratories, Llc Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3777833T3 (da) 2014-03-13 2023-12-18 Neuroderm Ltd Dopa-decarboxylase-inhibitorsammensætninger
JP6982870B2 (ja) 2015-05-06 2021-12-17 シンアジャル コーポレイション 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787581A (en) 1970-03-24 1974-01-22 M Sandler Pharmaceutical compositions and methods of treatment
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
JPS6327428A (ja) 1988-02-05
KR890001533A (ko) 1989-03-27
NZ220631A (en) 1990-12-21
JP2572768B2 (ja) 1997-01-16
DE3779500T2 (de) 1993-01-21
AU7405387A (en) 1987-12-17
US5017607A (en) 1991-05-21
CA1303509C (en) 1992-06-16
DE3779500D1 (de) 1992-07-09
EP0252290A2 (de) 1988-01-13
PT85055A (pt) 1988-07-01
KR950002150B1 (ko) 1995-03-14
ES2042520T3 (es) 1993-12-16
GR880300058T1 (en) 1988-10-18
KR880000092A (ko) 1988-03-23
EP0252290A3 (en) 1990-01-24
AU605154B2 (en) 1991-01-10
EP0252290B1 (de) 1992-06-03
DE252290T1 (de) 1988-06-09
US4826875A (en) 1989-05-02
HUT43952A (en) 1988-01-28
PT85055B (pt) 1994-10-31

Similar Documents

Publication Publication Date Title
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
ATE161836T1 (de) 4-substituierte-2-deoxy-2,3-didehydro alpha-d- neuraminsäure antivirale derivate
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
ES2141706T3 (es) Formulaciones y su empleo en el tratamiento de enfermedades neurologicas.
SE8505112D0 (sv) Novel pharmacological compounds
NO904986D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
MC2025A1 (fr) Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
NO900697D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater.
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
NO172491C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksan-alkensyre-dervater
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
TH14574A (th) สารผสมทางเภสัชกรรม
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
NO164651C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminofenol-derivater.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time